1. Home
  2. VOYA vs TGTX Comparison

VOYA vs TGTX Comparison

Compare VOYA & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voya Financial Inc.

VOYA

Voya Financial Inc.

HOLD

Current Price

$95.88

Market Cap

8.6B

Sector

Finance

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$54.95

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VOYA
TGTX
Founded
1975
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Life Insurance
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.6B
8.5B
IPO Year
2012
2008

Fundamental Metrics

Financial Performance
Metric
VOYA
TGTX
Price
$95.88
$54.95
Analyst Decision
Buy
Buy
Analyst Count
12
8
Target Price
★ $107.83
$69.71
AVG Volume (30 Days)
840.6K
★ 1.4M
Earning Date
11-02-2026
11-06-2026
Dividend Yield
★ 1.91%
N/A
EPS Growth
1.94
★ 1746.67
EPS
★ 2.73
0.17
Revenue
★ $8,189,000,000.00
$2,785,000.00
Revenue This Year
N/A
$55.81
Revenue Next Year
$4.47
$37.36
P/E Ratio
★ $36.04
$311.47
Revenue Growth
★ 1.73
N/A
52 Week Low
$64.50
$26.76
52 Week High
$105.64
$59.30

Technical Indicators

Market Signals
Indicator
VOYA
TGTX
Relative Strength Index (RSI) 46.61 51.71
Support Level $92.30 $51.68
Resistance Level $104.18 $58.05
Average True Range (ATR) 2.04 2.17
MACD 0.30 -0.06
Stochastic Oscillator 44.29 64.75

Price Performance

Historical Comparison
VOYA
TGTX

About VOYA Voya Financial Inc.

Voya Financial Inc is a financial services company, which, through its subsidiaries, provides various investment, insurance, and retirement solutions to individual and institutional clients in the United States. Its products and services include tax savings plans, individual retirement accounts, group life insurance plans, and employee benefits products, among others. The company tailors each of its products to the needs of its customer base. It operates its business through three principal lines: Retirement, Investment Management and Employee Benefits.The majority revenue is from Retirement segment.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: